Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Satoko Oka

Showing results (31-40 of 99) with videos related to

Pageof 10
Sort By:
American Journal of Therapeutics|August 4, 2018
Delayed Onset of Azacitidine-Associated Pneumotitis: A Case ReportSatoko Oka, Kazuo Ono, Masaharu Nohgawa
Clinical Case Reports|April 12, 2018
Successful treatment of refractory TAFRO syndrome with elevated vascular endothelial growth factor using thyroxine supplementsSatoko Oka, Kazuo Ono, Masaharu Nohgawa
Pathology Oncology Research : POR|November 27, 2019
Clinical Effect of CD25 on the Prognosis of Diffuse Large B Cell Lymphoma with Secondary Central Nervous System RelapseSatoko Oka, Kazuo Ono, Masaharu Nohgawa
Anti-Cancer Drugs|January 15, 2020
Successful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemiaSatoko Oka, Kazuo Ono, Masaharu Nohgawa
Journal of Clinical Pharmacy and Therapeutics|September 19, 2019
Clinical effects of CD45 on the prognosis of extramedullary myeloma relapseSatoko Oka, Kazuo Ono, Masaharu Nohgawa
Leukemia & Lymphoma|March 11, 2017
Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomideSatoko Oka, Kazuo Ono, Masaharu Nohgawa
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|March 29, 2026
[Hematologic responses with favorable safety in three elderly patients with polycythemia vera treated with ropeginterferon alfa-2b]Satoko Oka, Yuina Ueda, Takaya Mitsuyoshi, et al.
International Journal of Hematology|April 29, 2025
Successful treatment of myeloid blast phase chronic myelogenous leukemia with the JAK2 V617 F mutation by combination therapy with asciminib and ropeginterferon alfa-2b in an elderly patientSatoko Oka, Yuina Akagi, Takaya Mituyoshi, et al.
Leukemia & Lymphoma|December 25, 2025
Reduced dose and shorter duration venetoclax regimens are effective for newly diagnosed acute myeloid leukemia patients not considered fit for intensive treatmentSatoko Oka, Yuina Ueda-Akagi, Takaya Mitsuyoshi, et al.
Internal Medicine (Tokyo, Japan)|October 29, 2025
Effective Treatment with Ruxolitinib and Ropeginterferon Alfa-2b for Refractory TAFRO-like SyndromeSatoko Oka, Yuina Ueda-Akagi, Takaya Mitsuyoshi, et al.
Pageof 10

Showing results (31-40 of 99) with videos related to

Sort By:
Pageof 10
American Journal of Therapeutics|August 4, 2018
Delayed Onset of Azacitidine-Associated Pneumotitis: A Case ReportSatoko Oka, Kazuo Ono, Masaharu Nohgawa
Clinical Case Reports|April 12, 2018
Successful treatment of refractory TAFRO syndrome with elevated vascular endothelial growth factor using thyroxine supplementsSatoko Oka, Kazuo Ono, Masaharu Nohgawa
Pathology Oncology Research : POR|November 27, 2019
Clinical Effect of CD25 on the Prognosis of Diffuse Large B Cell Lymphoma with Secondary Central Nervous System RelapseSatoko Oka, Kazuo Ono, Masaharu Nohgawa
Anti-Cancer Drugs|January 15, 2020
Successful treatment with brentuximab vedotin for relapsed and refractory adult T cell leukemiaSatoko Oka, Kazuo Ono, Masaharu Nohgawa
Journal of Clinical Pharmacy and Therapeutics|September 19, 2019
Clinical effects of CD45 on the prognosis of extramedullary myeloma relapseSatoko Oka, Kazuo Ono, Masaharu Nohgawa
Leukemia & Lymphoma|March 11, 2017
Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomideSatoko Oka, Kazuo Ono, Masaharu Nohgawa
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|March 29, 2026
[Hematologic responses with favorable safety in three elderly patients with polycythemia vera treated with ropeginterferon alfa-2b]Satoko Oka, Yuina Ueda, Takaya Mitsuyoshi, et al.
International Journal of Hematology|April 29, 2025
Successful treatment of myeloid blast phase chronic myelogenous leukemia with the JAK2 V617 F mutation by combination therapy with asciminib and ropeginterferon alfa-2b in an elderly patientSatoko Oka, Yuina Akagi, Takaya Mituyoshi, et al.
Leukemia & Lymphoma|December 25, 2025
Reduced dose and shorter duration venetoclax regimens are effective for newly diagnosed acute myeloid leukemia patients not considered fit for intensive treatmentSatoko Oka, Yuina Ueda-Akagi, Takaya Mitsuyoshi, et al.
Internal Medicine (Tokyo, Japan)|October 29, 2025
Effective Treatment with Ruxolitinib and Ropeginterferon Alfa-2b for Refractory TAFRO-like SyndromeSatoko Oka, Yuina Ueda-Akagi, Takaya Mitsuyoshi, et al.
Pageof 10